111 related articles for article (PubMed ID: 11182562)
1. High-efficiency astatination of antibodies using N-iodosuccinimide as the oxidising agent in labelling of N-succinimidyl 3-(trimethylstannyl)benzoate.
Lindegren S; Andersson H; Bäck T; Jacobsson L; Karlsson B; Skarnemark G
Nucl Med Biol; 2001 Jan; 28(1):33-9. PubMed ID: 11182562
[TBL] [Abstract][Full Text] [Related]
2. Chloramine-T in high-specific-activity radioiodination of antibodies using N-succinimidyl-3-(trimethylstannyl)benzoate as an intermediate.
Lindegren S; Skarnemark G; Jacobsson L; Karlsson B
Nucl Med Biol; 1998 Oct; 25(7):659-65. PubMed ID: 9804047
[TBL] [Abstract][Full Text] [Related]
3. Labeling of Anti-HER2 Nanobodies with Astatine-211: Optimization and the Effect of Different Coupling Reagents on Their in Vivo Behavior.
Dekempeneer Y; Bäck T; Aneheim E; Jensen H; Puttemans J; Xavier C; Keyaerts M; Palm S; Albertsson P; Lahoutte T; Caveliers V; Lindegren S; D'Huyvetter M
Mol Pharm; 2019 Aug; 16(8):3524-3533. PubMed ID: 31268724
[TBL] [Abstract][Full Text] [Related]
4. Astatine-211-labeled antibodies for treatment of disseminated ovarian cancer: an overview of results in an ovarian tumor model.
Andersson H; Elgqvist J; Horvath G; Hultborn R; Jacobsson L; Jensen H; Karlsson B; Lindegren S; Palm S
Clin Cancer Res; 2003 Sep; 9(10 Pt 2):3914S-21S. PubMed ID: 14506189
[TBL] [Abstract][Full Text] [Related]
5. Direct procedure for the production of 211At-labeled antibodies with an epsilon-lysyl-3-(trimethylstannyl)benzamide immunoconjugate.
Lindegren S; Frost S; Bäck T; Haglund E; Elgqvist J; Jensen H
J Nucl Med; 2008 Sep; 49(9):1537-45. PubMed ID: 18703591
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biodistribution of 211At-labeled, biotinylated, and charge-modified poly-L-lysine: evaluation for use as an effector molecule in pretargeted intraperitoneal tumor therapy.
Lindegren S; Andersson H; Jacobsson L; Bäck T; Skarnemark G; Karlsson B
Bioconjug Chem; 2002; 13(3):502-9. PubMed ID: 12009939
[TBL] [Abstract][Full Text] [Related]
7. Biokinetics of the monoclonal antibodies MOv 18, OV 185 and OV 197 labelled with 125I according to the m-MeATE method or the Iodogen method in nude mice with ovarian cancer xenografts.
Andersson H; Lindegren S; Bäck T; Jacobsson L; Leser G; Horvath G
Acta Oncol; 1999; 38(3):323-8. PubMed ID: 10380823
[TBL] [Abstract][Full Text] [Related]
8. Synthesis of radioiodinated N-succinimidyl iodobenzoate: optimization for use in antibody labelling.
Garg PK; Archer GE; Bigner DD; Zalutsky MR
Int J Rad Appl Instrum A; 1989; 40(6):485-90. PubMed ID: 2551846
[TBL] [Abstract][Full Text] [Related]
9. Comparative tissue distribution in mice of the alpha-emitter 211At and 131I as labels of a monoclonal antibody and F(ab')2 fragment.
Garg PK; Harrison CL; Zalutsky MR
Cancer Res; 1990 Jun; 50(12):3514-20. PubMed ID: 2340501
[TBL] [Abstract][Full Text] [Related]
10. Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.
Zalutsky MR; Garg PK; Friedman HS; Bigner DD
Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7149-53. PubMed ID: 2476813
[TBL] [Abstract][Full Text] [Related]
11. Radiopharmaceutical chemistry of targeted radiotherapeutics, Part 3: alpha-particle-induced radiolytic effects on the chemical behavior of (211)At.
Pozzi OR; Zalutsky MR
J Nucl Med; 2007 Jul; 48(7):1190-6. PubMed ID: 17574991
[TBL] [Abstract][Full Text] [Related]
12. Single-cell irradiation from [211At] astatine-labeled C215 monoclonal antibody: improved estimates of radiosensitivity from measurements on cellular uptake and retention.
Palm S; Bäck T; Claesson I; Delle U; Hultborn R; Lindegren S; Jacobsson L
Anticancer Res; 2003; 23(2B):1219-21. PubMed ID: 12820374
[TBL] [Abstract][Full Text] [Related]
13. Shelf-life of ɛ-lysyl-3-(trimethylstannyl)benzamide immunoconjugates, precursors for 211At labeling of antibodies.
Aneheim E; Halleröd J; Albertsson P; Jensen H; Holgersson S; Lindegren S
Cancer Biother Radiopharm; 2015 Feb; 30(1):41-5. PubMed ID: 25588020
[TBL] [Abstract][Full Text] [Related]
14. Optimized indirect (76)Br-bromination of antibodies using N-succinimidyl para-[76Br]bromobenzoate for radioimmuno PET.
Höglund J; Tolmachev V; Orlova A; Lundqvist H; Sundin A
Nucl Med Biol; 2000 Nov; 27(8):837-43. PubMed ID: 11150718
[TBL] [Abstract][Full Text] [Related]
15. Cellular processing in the SW1222 cell line of mAb A33 directly and indirectly radiohalogenated.
Höglund J; Orlova A; Sundin A; Lundqvist H; Tolmachev V
Oncol Rep; 2006 Jul; 16(1):159-63. PubMed ID: 16786140
[TBL] [Abstract][Full Text] [Related]
16. In vitro characterization of 211 At-labeled antibody A33--a potential therapeutic agent against metastatic colorectal carcinoma.
Almqvist Y; Orlova A; Sjöström A; Jensen HJ; Lundqvist H; Sundin A; Tolmachev V
Cancer Biother Radiopharm; 2005 Oct; 20(5):514-23. PubMed ID: 16248767
[TBL] [Abstract][Full Text] [Related]
17. Astatination of proteins using an N-succinimidyl tri-n-butylstannyl benzoate intermediate.
Zalutsky MR; Narula AS
Int J Rad Appl Instrum A; 1988; 39(3):227-32. PubMed ID: 2836342
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and Evaluation of Astatinated N-[2-(Maleimido)ethyl]-3-(trimethylstannyl)benzamide Immunoconjugates.
Aneheim E; Gustafsson A; Albertsson P; Bäck T; Jensen H; Palm S; Svedhem S; Lindegren S
Bioconjug Chem; 2016 Mar; 27(3):688-97. PubMed ID: 26791409
[TBL] [Abstract][Full Text] [Related]
19. In vitro evaluation of the astatinated chimeric monoclonal antibody U36, a potential candidate for treatment of head and neck squamous cell carcinoma.
Nestor M; Persson M; van Dongen GA; Jensen HJ; Lundqvist H; Anniko M; Tolmachev V
Eur J Nucl Med Mol Imaging; 2005 Nov; 32(11):1296-304. PubMed ID: 16028065
[TBL] [Abstract][Full Text] [Related]
20. In vitro evaluation of avidin antibody pretargeting using 211At-labeled and biotinylated poly-L-lysine as effector molecule.
Frost SH; Jensen H; Lindegren S
Cancer; 2010 Feb; 116(4 Suppl):1101-10. PubMed ID: 20127953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
